May 19, 2015

Kineticos Expands Biopharmaceutical Practice Leadership Team with Two Senior Executive Appointments

Kineticos, a specialized management consulting firm serving the life sciences industry, today announced the expansion of its Biopharmaceutical practice leadership team with the additions of Dee Parson Grange, Senior Vice President, and Mark Osterman, Senior Vice President. Both executives will report to James Forte, Managing Director of the Biopharmaceutical practice at Kineticos.

Dee Parson Grange joins Kineticos as a seasoned executive with more than 25 years of experience achieving strategic and operational business goals for both large pharmaceutical and private biotech companies. Prior to Kineticos, Ms. Parson Grange served in various cross-functional leadership roles at Bayer Pharmaceutical, Bayer Biologic Products (now part of Grifols), and Biolex Therapeutics. In addition, she has provided consulting services to global biopharmaceutical companies targeting rare diseases, biosimilars, biobetters, and novel therapeutic proteins. She holds a BS in Biology from Graceland University and a global executive MBA from the Fuqua School of Business at Duke University.

Mark Osterman also has over 25 years of experience in the biopharmaceutical industry. He started his career with 11 years at GlaxoSmithKline with roles of increasing responsibility in sales, clinical, and marketing before moving to Johnson & Johnson. At J&J, he was Vice President of the Johnson & Johnson Development Corporation and launched their stem cell internal venture. He also was responsible for the cardiovascular, pulmonary, metabolic, and mimetibody therapeutic areas in the Global Biologic Strategic Marketing group before being recruited to Discovery Labs. Mr. Osterman was Senior Vice President and responsible for commercial operations and business development at Discovery Labs before serving as Vice President of Global Marketing at Solstice Neurosciences. Immediately prior to joining Kineticos, he founded the Osterman Strategy Group, a boutique management consulting firm, where he worked with large and emerging biopharmaceutical companies as well as medical device companies to help solve their most challenging business issues. Mr. Osterman earned a dual BA in Business Management and Economics from North Carolina State University.

“Dee and Mark add extensive cross-functional experience to the practice along with an impressive track record of bringing new biopharmaceutical products to market across various therapeutic areas and geographies,” stated Mr. Forte. “Their expertise adds depth to our existing consulting capabilities and credibility to our practice as an increasing number of biopharma clients depend on our team to guide their path to market,” he continued.

About the Biopharmaceutical Practice at Kineticos

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels. The firm’s consulting team members have a depth of expertise across functional areas and therapeutic areas, established through decades of work in consulting and in industry. Overall, the practice has a strong commitment to client satisfaction and a proven ability to deliver results through practical solutions. The Biopharmaceutical practice at Kineticos supports clients across three service areas including corporate strategy, corporate development, and commercial strategy. For more information on the Biopharmaceutical practice at Kineticos, please visit